Pharmacology of the short QT syndrome N588K-hERG K(+) channel mutation: differential impact on selected class I and class III antiarrhythmic drugs

Ítems similars

• Increased Vulnerability of Human Ventricle to Re-entrant Excitation in hERG-linked Variant 1 Short QT Syndrome
  per: Adeniran, Ismail, et al.
  Publicat: (2011)
• hERG1a/1b heteromeric currents exhibit amplified attenuation of inactivation in variant 1 short QT syndrome
  per: McPate, M.J., et al.
  Publicat: (2009)
• Action Potential Clamp and Pharmacology of the Variant 1 Short QT Syndrome T618I hERG K(+) Channel
  per: El Harchi, Aziza, et al.
  Publicat: (2012)
• Action potential clamp and pharmacology of the variant 1 Short QT Syndrome T618I hERG K⁺ channel.
  per: Aziza El Harchi, et al.
  Publicat: (2012-01-01)
• Functional and pharmacological characterization of an S5 domain hERG mutation associated with short QT syndrome
  per: Butler, Andrew, et al.
  Publicat: (2019)